167results about How to "Improve skin appearance" patented technology

Devices, systems, and methods treat cosmetic defects, and often apply cooling with at least one tissue-penetrating probe inserted through of the skin of a patient. The cooling may remodel one or more target tissue so as to effect a desired change in a composition of the target tissue and/or a change in its behavior. Exemplary embodiments of the cooling treatments will interfere with the nerve/muscle contractile function chain so as to mitigate wrinkles of the skin. Related treatments may be used therapeutically for treatment of back and other muscle spasms, chronic pain, and the like. Some embodiments may remodel subcutaneous adipose tissue so as to alter a shape or appearance of the skin surface.

A topical cosmetic composition including: at least one water-soluble cosmetic agent; at least one oil-soluble cosmetic agent; and a dermal penetration enhancer, wherein topical application of the composition results in the delivery of the water-soluble and oil-soluble cosmetic agents into the stratum corneum as well as delivery of the oil-soluble cosmetic agent into the epidermis and dermis.

Topical skin care compositions are provided for the improvement of the appearance of the skin, namely of the skin comprising the face, surrounding the eyes, mouth, and hands, as well as the skin of the body. The skin care compositions include synergistic combinations of active peptide ingredients that are specially formulated to enhance the natural appearance of the face, hands, and/or body. Specifically, the synergistic skin care compositions may be applied to one or more of the skin surrounding the eyes, mouth, nose, forehead, ears, neck, hands, feed, and overall body to give the skin thereof a cleaner, smoother and more wrinkle free appearance.

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.

This invention relates to compositions comprising an ethanolamine derivative and an organic salt of zinc and/or magnesium. It further relates to the use of such compositions in topical formulations, in particular in anti-aging formulations. The invention further relates to the use of such compositions to promote human dermal fibroblasts growth and to combat the effects of skin aging.

This invention relates to stable compositions comprising an ethanolamine derivative and one or more glucosides (in particular melibiose and lactose). It further relates to the use of such compositions in cosmetic preparations, in particular in anti-aging formulations. The invention further relates to the use of such compositions to promote normal human dermal fibroblasts growth and to stimulate collagen synthesis. It further concerns a process for preparing such compositions.

An exemplary treatment system can be provided which can include a laser system configured to emit at least one laser beam, and an optical system configured to focus the laser beam(s) to a focal region at a selected distance from a surface of a tissue. The focal region can be configured to illuminate at least a portion of a target. The optical system can cause an irradiation energy transferred to the focal region of the laser beam(s) to (i) generate a plasma in a first region of the tissue adjacent to the target, and (ii) avoid a generation of a plasma in a second region of the tissue. The optical system has a numerical aperture that is in the range of about 0.5 to about 0.9. An exemplary method can also be provided to control such treatment system.

A non-user controllable electro-therapy device has a housing for a microprocessor, power source, status indicator, activation switch, and one or more channels for electrode contact. Only the activation switch is user-accessible. The microprocessor generates a non-user controllable frequency dependent mixed electrical signal through the electrodes, wherein the mixed electrical signal is a combination of at least two different frequencies, a first frequency having a first minimum and maximum microamp range and a second frequency having a different second minimum and maximum microamp range. The higher of the two frequencies is superimposed on the lower frequency, creating a current intensity window as an envelope along a profile of the lower frequency. The mixed electrical signal is automatically applied for a pre-determined period of time, and amplitude and/or duration and/or frequencies is varied according to a pre-set schedule programmed into a controller coupled to the one or more electrodes.

The present invention related to cosmetic compositions comprising oridonin and new cosmetic uses. Oridonin is used for fighting the signs of cutaneous aging and for slimming. A composition comprising a combination of oridonin and darutigenol or a derivative thereof, in particular darutoside, is disclosed together with the cosmetic use of such composition.

The topical use of a skin commensal prebiotic to improve the health of the skin microbiome, thereby potentially improving the condition and/or appearance of the skin, and topical cosmetic compositions that include the skin commensal prebiotic. The topical cosmetic compositions may include a dermatologically acceptable carrier and an effective amount of prebiotic, and may be used in conjunction with one or more oral or topical prebiotics, probiotics and/or probiotic lysates.

There are disclosed topical compositions for alleviation of skin irritation symptoms or conditions having at least one plant extract effective to inhibit COX-2 enzyme, NGF protein, and/or TNF-alpha protein activity. Preferably, the compositions have a cosmetically, dermatologically, or pharmaceutically acceptable vehicle. In addition to the enzyme inhibitory plant material and acceptable vehicle, compositions may also have at least one active ingredient known to produce skin irritation. There is also a method for treatment of skin irritation symptoms or conditions involving topically applying compositions of the invention. Also disclosed are compositions and methods for topical administration of compositions to the skin that improve the aesthetic appearance of skin and/or provide an anti-aging benefit to the skin.